Imatinib, the first TKI introduced for the treatment of newly diagnosed CML patients, inactivates the BCR-ABL kinase to uncouple the many cell processes creating the leukemic state. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.